Multi-Omics Profiling of Semaglutide Effects on Diabetic Cognitive Impairment

A 12-week study in a mouse model of diabetic cognitive impairment (DCI) integrates fecal shotgun metagenomics, targeted bile acid profiling, cerebral proteomics, and metabolomics. The dataset documents the neuroprotective effects of semaglutide (SE) treatment, linking gut microbiota remodeling to modulation of cerebral sphingolipid pathways.

Use Cases

• Analyze fecal metagenomics data to correlate microbial α-diversity and genera like Bacteroides or Desulfovibrio with treatment outcomes.
• Model the relationship between cerebral bile acid profiles and the expression levels of sphingolipid pathway enzymes SGPP1 and CERS2.
• Investigate weight-dependent versus weight-independent effects by comparing ABCA2 transporter modulation to behavioral and synaptic integrity assessments.

Strengths

• Integrates four distinct omics data types: metagenomics, bile acid profiling, proteomics, and metabolomics.
• Data originates from a controlled 12-week animal study with confirmed therapeutic efficacy via behavioral and histological tests.
• Published under a permissive CC BY 4.0 license.

Limitations

• Dataset scope is limited, contained within a single 918.7 KB DOCX file, suggesting it is a summary table rather than raw experimental data.
• Data is derived solely from a mouse model, limiting direct applicability to human clinical contexts.
• The specific row and column counts, sample sizes, and data granularity are unknown from the provided description.

Provenance

Source

Liqin Qi via figshare

Collection Method

Integrative multi-omics approach applied to a mouse model of diabetic cognitive impairment over a 12-week semaglutide treatment period.

Time Range

Covers a 12-week experimental treatment period.

Freshness

Last updated March 26, —.

Geography

null